S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2011-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s10549-010-0982-0PMID 20556507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigenetics in cancer.

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

  2009influential reference
• DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

  2009influential reference
• Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

  2009cited by this paper
• Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

  2008cited by this paper
• A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

  2008cited by this paper
• Down-regulation of Enhancer of Zeste-2 decreases growth of estrogen receptor negative invasive breast carcinoma and requires BRCA1

  2008cited by this paper
• Epigenetics in cancer.

  2008cited by this paper
• DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.

  2008cited by this paper
• Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.

  2008influential reference
• EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer

  2008cited by this paper
• BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells.

  2008influential reference
• BAG-1 inhibits PPARγ-induced cell death, but not PPARγ-induced transcription, cell cycle arrest or differentiation in breast cancer cells

  2008influential reference
• Roles of the EZH2 histone methyltransferase in cancer epigenetics.

  2008cited by this paper
• Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.

  2007cited by this paper
• Cancer genetics of epigenetic genes.

  2007cited by this paper
• EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor

  2007cited by this paper
• Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells

  2007cited by this paper
• Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

  2006cited by this paper
• EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

  2006cited by this paper
• The Polycomb group protein EZH2 directly controls DNA methylation

  2006cited by this paper
• John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity.

  2005cited by this paper
• Polycomb group protein ezh2 controls actin polymerization and cell signaling.

  2005cited by this paper
• Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

  2005cited by this paper
• Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3

  2005cited by this paper
• John Montgomery's Legacy: Carbocyclic Adenosine Analogues as Sah Hydrolase Inhibitors with Broad-Spectrum Antiviral Activity

  2005influential reference
• Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

  2004cited by this paper
• Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A

  2004cited by this paper
• EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer

  2003cited by this paper
• EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

  2003cited by this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

  2001cited by this paper
• The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development

  2001cited by this paper
• The Polycomb-Group Gene Ezh2 Is Required for Early Mouse Development

  2001cited by this paper
• Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

  2000cited by this paper
• Polycomb group protein complexes: do different complexes regulate distinct target genes?

  1999cited by this paper
• Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation

  1999influential reference
• Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation.

  1997cited by this paper
• Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres

  1997cited by this paper
• Nile red: a selective fluorescent stain for intracellular lipid droplets

  1985cited by this paper

• In vitro investigations of troxacitabine (TROX) and 3'-deazanepanocin (DZNep) combination for pancreatic cancer therapy.

  2026cites this paper
• Multidimensional Roles of EZH2 and Its Therapeutic Potential in Cancer TherapyReview Article

  2025cites this paper
• Anticancer Activity of Enantiomeric Neplanocins A: Exploring the Role of Chirality in Tumor Suppression

  2025cites this paper
• TXNIP in cancer: Unlocking biological insights and tackling clinical challenges.

  2025cites this paper
• A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis

  2025cites this paper
• Decoding the Epigenome of Breast Cancer

  2025cites this paper
• Investigation of anti-cancer efficiency of DZNep and Stauprimide combination in breast cancer

  2025cites this paper
• A novel interplay between PRC2 and miR‐3189 regulates epithelial–mesenchymal transition (EMT) via modulating COL6A2 in glioblastoma

  2024cites this paper
• Recent Advances in enhancer of zeste homolog 2 Inhibitors: Structural insights and therapeutic applications.

  2024cites this paper
• 5'-Noraristeromycin Repurposing: Well-known S-Adenosyl-L-homocysteine Hydrolase Inhibitor As a Potential Drug Against Leukemia

  2024cites this paper
• Epigenetic regulation of androgen dependent and independent prostate cancer.

  2024cites this paper
• Targeting one‐carbon metabolism for cancer immunotherapy

  2024cites this paper
• Epigenetic Abnormalities in Chondrosarcoma

  2023cites this paper
• The Heightened Importance of EZH2 in Cancer Immunotherapy

  2023cites this paper
• EZH2: An Accomplice of Gastric Cancer

  2023cites this paper
• Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors

  2022cites this paper
• The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy

  2022cites this paper
• Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG)

  2022cites this paper
• Wumei Pill Ameliorates AOM/DSS-Induced Colitis-Associated Colon Cancer through Inhibition of Inflammation and Oxidative Stress by Regulating S-Adenosylhomocysteine Hydrolase- (AHCY-) Mediated Hedgehog Signaling in Mice

  2022cites this paper
• Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor

  2022cites this paper
• Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way

  2021cites this paper
• Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity

  2021cites this paper
• The molecular mechanisms and therapeutic potential of EZH2 in breast cancer.

  2021cites this paper
• Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling

  2021cites this paper
• The Role of CHK1 Varies with the Status of Oestrogen-receptor and Progesterone-receptor in the Targeted Therapy for Breast Cancer

  2020cites this paper
• Epigenetic-mediated apoptosis in aggressive B-cell lymphomas

  2020cites this paper
• Pharmacologic downregulation of protein arginine methyltransferase1 expression by adenosine dialdehyde increases cell senescence in breast cancer.

  2020cites this paper
• A novel route to a chiral building block for the preparation of cyclopentenyl carbocyclic nucleosides. Synthesis and anticancer activity of enantiomeric neplanocins A

  2020cites this paper
• Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM

  2020cites this paper
• Symphony of epigenetic and metabolic regulation—interaction between the histone methyltransferase EZH2 and metabolism of tumor

  2020cites this paper
• Inhibition of methyltransferase activity of enhancer of zeste 2 leads to enhanced lipid accumulation and altered chromatin status in zebrafish

  2020cites this paper
• Pharmacoepigenetics of EZH2 Inhibitors

  2019cites this paper
• Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators.

  2019cites this paper
• Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: Role of apolipoprotein E

  2019influential citation
• EZH2 inhibitor DZNep modulates microglial activation and protects against ischaemic brain injury after experimental stroke.

  2019cites this paper
• CD133 in Breast Cancer Cells: More than a Stem Cell Marker

  2019cites this paper
• The synergistic effect of DZ‑NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.

  2019cites this paper
• Targeting of Epigenetic Modifier EZH2 in Oropharyngeal Squamous Cell Carcinomas

  2018cites this paper
• Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and - pyrimidines.

  2018cites this paper
• Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation

  2018cites this paper
• Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis

  2017cites this paper
• EGFR family inhibition identifies p 38 MAPK as a potential therapeutic target in bladder cancer

  2017cites this paper
• Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.

  2017cites this paper
• Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.

  2017cites this paper
• Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas

  2017cites this paper
• Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.

  2017cites this paper
• Functional and therapeutic significance of EZH2 in urological cancers

  2017cites this paper
• The Link Between Hyperhomocysteinemia and Hypomethylation: Implications for Cardiovascular Disease

  2017cites this paper
• Synthesis and biological evaluation of substituted indazolyl amide derivatives as S-adenosyl-l-homocysteine hydrolase inhibitors

  2016cites this paper
• Scope, limitations and classification of lactamases.

  2016cites this paper
• Targeting EZH2 in cancer

  2016cites this paper
• Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells

  2016cites this paper
• EZH2, an on-off valve in signal network of tumor cells.

  2016cites this paper
• Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells

  2016cites this paper
• Rational Design of a Profluorescent Substrate for S-adenosylhomocysteine Hydrolase and its Applications in Bioimaging and Inhibitor Screening.

  2016cites this paper
• Control of fluxes in metabolic networks

  2016cites this paper
• Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential

  2016cites this paper
• Epigenetic modulators as therapeutic targets in prostate cancer

  2016cites this paper
• HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells

  2015cites this paper
• Lactogenic hormone stimulation and epigenetic control of L‐amino acid oxidase expression in lactating mammary glands

  2015cites this paper
• Targeting of cancer stem cells by inhibitors of DNA and histone methylation

  2015cites this paper
• Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.

  2015cites this paper
• The role of polycomb repressive complexes in biliary tract cancer

  2015cites this paper
• Control principles of metabolic networks

  2015cites this paper
• Crystal structures of S-adenosylhomocysteine hydrolase from the thermophilic bacterium Thermotoga maritima.

  2015cites this paper
• Targeting EZH2 for Cancer Therapy: Progress and Perspective

  2015cites this paper
• Utilising quantitative immunoproteomics to reveal differential autoantibody biomarker panels in serous ovarian cancer patients

  2015cites this paper
• EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

  2015cites this paper
• HMBD and 5-AzadC combination reverses tumor suppressor CCAAT/enhancer binding protein delta to strengthen the death of liver cancer cells

  2015cites this paper
• 1 HMBD and 5-AzadC combination reverses tumor suppressor CCAAT/enhancer binding protein delta to strengthen the death of liver cancer cells

  2015cites this paper
• 3‐Deazaneplanocin A and Neplanocin A Analogues and Their Effects on Apoptotic Cell Death

  2015cites this paper
• Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)

  2015cites this paper
• Induction of the mesenchymal to epithelial transition by demethylation‐ activated microRNA‐200c is involved in the anti‐migration/invasion effects of arsenic trioxide on human breast cancer cells

  2015cites this paper
• Design and synthesis of amide derivatives as S-adenosyl-L-homocysteine hydrolase inhibitors.

  2014cites this paper
• Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer

  2014cites this paper
• Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.

  2014cites this paper
• PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.

  2014cites this paper
• The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.

  2014cites this paper
• Overexpression of S-adenosylhomocysteine hydrolase (SAHH) in esophageal squamous cell carcinoma (ESCC) cell lines: effects on apoptosis, migration and adhesion of cells

  2014cites this paper
• Investigation of approaches for overcoming chemoresistance in pancreatic cancer

  2014influential citation
• 3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells

  2014cites this paper
• Regulation and Role of EZH2 in Cancer

  2014cites this paper
• DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.

  2013cites this paper
• A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.

  2013cites this paper
• Cancer Stem Cells: The Gist of the Matter

  2013cites this paper
• In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness

  2013influential citation
• Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies

  2013cites this paper
• Epigenetic targeting therapies to overcome chemotherapy resistance.

  2013cites this paper
• Epigenetic Alterations in Oncogenesis

  2013cites this paper
• Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer.

  2013cites this paper
• Chapter 7 Molecular mechanisms involved in the synergistic interaction of the EZH 2 inhibitor 3-deazaneplanocin A ( DZNeP ) with gemcitabine in pancreatic cancer cells

  2013cites this paper
• Causal analysis approaches in Ingenuity Pathway Analysis

  2013cites this paper
• EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD

  2013cites this paper
• A fluorescence-based assay for the measurement of S-adenosylhomocysteine hydrolase activity in biological samples.

  2013cites this paper
• High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer

  2012cites this paper
• Pericellular pH homeostasis is a primary function of the Warburg effect: Inversion of metabolic systems to control lactate steady state in tumor cells

  2012cites this paper
• 2-Azabicyclo[2.2.1]hept-5-en-3-one: chemical profile of a versatile synthetic building block and its impact on the development of therapeutics.

  2012cites this paper
• Assays for methionine γ-lyase and S-adenosyl-L-homocysteine hydrolase based on enzymatic formation of CdS quantum dots in situ.

  2012cites this paper
• Oncoepigenomics: making histone lysine methylation count.

  2012cites this paper
• The role of histone methyltransferase EZH2 in myelodysplastic syndromes

  2012cites this paper